Innosuisse & Basel-Stadt present new funding schemes stimulating science-based innovation mitigating the impact of Covid-19
Webinar on Wednesday, February 3, 2021
- Impact of Covid pandemic on Swiss biotech companies, Michael Altorfer, CEO, Swiss Biotech Association
- Basel-Stadt subordinated loan guarantee program:
- Purpose, objectives, and design, Samuel Hess, Department of Economic, Social and Environmental Affairs, Basel-Stadt
- Target companies and application process, Felix Kohlermann, Department of Economic, Social and Environmental Affairs, Basel-Stadt
- Legal aspects (loan & warrant agreements), Matthias Staehelin, President BioValley, VISCHER Anwälte
- Federal innovation impulse program “Swiss Innovation Power”, Stéphanie Lecaudé, Scientific Officer Life Sciences, Innosuisse
- Value of Basel-Stadt and Innosuisse innovation programs from the perspectiveof other regions, René Hausammann, President, Swissparks.ch
Watch the recording here:
Swiss Biotech Association Stauffacherstrasse 16
VISCHER is supporting the organisers for this event.
Financing and Business Development in the times of COVID-19
Webinar on Thursday, 24 September, 2020
Organizers: BioValley Basel Association and BioValley Business Angels Club
The coronavirus is changing our society, our economy and our lifestyle. In this second webinar, CEOs and Board members from the BioValley cluster share their experience how to build companies in this new environment.
– Alexander Bausch, CEO Kinarus
– Derek Brandt, Board member Resistell, LiVET and Chairman ender diagnostics
– Martin Gertsch, Chairman of ARTIDIS, Board member Santhera
– Werner Tschollar, Chairman and/or CEO of Amyra, CanVirex and EsoCap
– Marina Udier, CEO Nouscom
Alexander Bausch serves as Chief Executive Officer and member of the Kinarus Board of Directors. Kinarus has licensed Pamapimod, a clinical stage P38 inhibitor from Hoffmann-La Roche and is ready to star a Phase 2 clinical trial as oral treatment in wet AMD. Alexander Bausch has extensive business, development and executive leadership expertise from a 20 year career in the pharmaceutical industry. While at Hoffmann-La Roche, he led Research and Development teams across seven therapeutic areas, most recently as Life Cycle Leader for a global phase 3 program where he developed the strategic roadmap for commercialization up to product launch. He has entered more than ten drugs into clinical development including four molecules successfully into phase 2 and one into phase 3. Alexander Bausch is a pharmacist by training and obtained his Ph.D. from the University of Basel.
Derek Brandt is a Board member of Resistell in Muttenz, Board member of LiVET in Bern as well as Chairman of the Board of ender diagnostics in Bern. He is Senior Global Vice President Advanced Technologies at Gerresheimer and Stiftungsrat of Fachhochschule Nordwestschweiz (FHNW). From 2007 to 2018, Derek Brandt was CEO of Sensile Medical (sold to Gerresheimer). He studied at the UCB (Pharmacokinetics), University of Berne (Applied Statistics) and University of Applied Sciences Basel (Chemistry).
Martin Gertsch is Chairman of ARTIDIS, in Basel, a Board member of Santhera and a Board Member of the University Center of Dentistry, Basel (UZB). Up to 2014, he served as Chief Financial Officer of Acino Holding. Prior to this he was Vice President Head of Finance EMEA at Synthes and held Chief Financial Officer and Chief Operating Officer positions at Delenex Therapeutics and ESBATech, two biotech companies. From 2002 to the beginning of 2006, he was Chief Financial Officer of Straumann, which he had joined in 1997 as Head of Group Controlling and Reporting. Between 1986 and 1997, Martin was an Audit Engagement Manager at PricewaterhouseCoopers, Basel, Switzerland. Martin is a Swiss-certified fiduciary and Swiss-certified public accountant.
Werner Tschollar is Chairman and/or CEO of Amyra, CanVirex and EsoCap, all in Basel. He has extensive industry experience in pharmaceuticals and biotechnology. He held senior executive positions at BMS, Schering-Plough and Novartis and founded several biotech companies. Werner studied medicine and pharmacy, is trained in internal medicine and is a board certified clinical pharmacologist. He also holds an MBA degree and is a Fellow of the American College of Cardiology.
Marina Udier is CEO of Nouscom in Basel, an immuno-oncology company developing off-the-shelf and personalized cancer neoantigen vaccines. She joined Nouscom in 2016 as the Chief Operating Officer from Versant Ventures where she was an Operating Principal. Prior to Versant, Marina was at Novartis Pharma in Basel in various senior development and commercial roles. As the Global Commercial Head, Near Patient Testing Unit, she developed the global strategy for a point of care diagnostics platform. Her experience in molecular diagnostics includes In Vitro Diagnostics development; she led development of a Companion Diagnostics for RYDAPT™, the first approved AML drug in over 3 decades. Marina managed the Global Neurodegeneration portfolio for Novartis driving her Brands to a blockbuster status. Marina spent 5 years with McKinsey & Company in Chicago, working with Healthcare Fortune 500 companies in areas of marketing, strategy and pricing. Marina received her PhD in Chemistry from Yale University. She authored peer reviewed publications covering HIV/AIDS research.
Chair: Matthias Staehelin; President BioValley Basel
Tackling Corona – Experts report on activities in and from the BioValley
Webinar Wednesday, 17 June, 2020, organized by BioValley BioValley Basel Association, BioValley Deutschland e.V. and BioValley France.
Experts from the BioValley cluster (and close by) reported on efforts to diagnose the virus, manufacture the vaccine and find a cure.
· Tim Pfister, CEO ender diagnostic, Bern,
· Thierry Paper, Founder and Deputy Managing Director Biosynex, Strasbourg
· Dr. Dirk Redlich, Vice-President, Head CMC Development and Clinical Trial Material (CTM) Production & Dr. Claudio Thomasin, Director R&D, Janssen Vaccines, Bern
· Dr. Hubertus Schleer and Dr Iwona Budnicki, Aldevron Freiburg i.B.
· Dr. Karsten Fischer, CEO Memo Therapeutics, Schlieren
· Sai Reddy, Professor of Systems and Synthetic Immunology at ETHZ in Basel
The coronavirus is changing our society, our economy and our lifestyle. Experts from the BioValley cluster (and close by) reported on efforts to diagnose the virus, manufacture the vaccine and find a cure.
Introduction: Matthias Staehelin, President BioValley
Diagnose SARS-CoV-2 by a molecular biological rapid test in 30 minutes: Tim Pfister, CEO ender diagnostic, Bern
Rapid Diagnostic Tests (RDTs) made in France: Challenge of Scale-up and Self-testing: Thierry Paper, Founder and Deputy Managing Director Biosynex, Strasbourg
The Janssen COVID-19 vaccine program: Dr. Dirk Redlich, Vice-President, Head CMC Development and Clinical Trial Material (CTM) Production & Dr. Claudio Thomasin, Director R&D, Janssen Vaccines, Bern
Rapid discovery of humanized antibodies against SARS-CoV-2 targets utilizing the OmniRat® platform and Berkeley Lights’ Beacon® instrument: Dr. Hubertus Schleer and Dr Iwona Budnicki, Aldevron Freiburg i.B.
The HACK CORONA INITIATIVE to identify therapeutic monoclonal antibodies against SARS-CoV-2: Dr. Karsten Fischer, CEO Memo Therapeutics, Schlieren
Antibody discovery against SARS-CoV-2 by deep sequencing, machine learning and genome editing: Sai Reddy, Professor of Systems and Synthetic Immunology at ETHZ in Basel
Annual Event of BioValley Basel and BioBAC 2019
BioValley Business Angels Club BioBAC and BioValley Basel Association have hold their annual event on Thursday, 26th of September 2019
Topic: University & Start-ups – a love affair?
University Vice-Rector Torsten Schwede talked at the annual event with more than 100 participants. He introduced the new entrepreneurial innovation initiative of the University of Basel, which seeks to support innovation to increase societal impact.
T3 Pharmaceuticals CEO Simon Ittig reported on the positive experiences of the start-up: In his view, key success factors are the will of society, politicians and university to support emerging companies, infrastructure and access to non-dilutive financial support. As an example of an early-stage company, Aukera, a project developing an mTOR drug discovery platform, sought further support and managed to get first contacts with experienced professionals at the event. Thereafter the CEOs of three Start- Up show-cases (Resistell, Inthera Bioscience and AOT – Advanced Osteotomy Tools) presented their companies.
One participant commented: “..extremely interesting and excellent presentations where one could feel the personal engagement behind the individual projects”
Immediately prior to the event Trudi Haemmerli (PerioC and TruStep Consulting, Board member Innosuisse) and Christian Elias Schneider (Head of Innovation & Entrepreneurship University of Basel) were elected to the Board of BioValley Basel. A very warm welcome to both of them!